Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced that Dr. Christian Homsy, Chief Executive Officer, will present and participate in a panel discussion at the upcoming Gene and Cell Therapy Meeting on the Mesa being held October 5-7, 2016 in La Jolla, CA, USA.

Dr. Homsy will present during the Partnering Forum event on Wednesday, October 5, 2016 at 11:15 a.m. Pacific Time. He will discuss Celyad’s recent developments and clinical progress of the engineered T-cell product candidate, NKR-2, for the treatment of cancer.

Dr. Christian Homsy, CEO of Celyad, commented, “I am excited to present our unique natural killer receptor T-cell asset and participate in the panel discussion at Meeting on the Mesa, one of the preeminent conferences in our industry. I look forward to sharing the stage with fellow leaders in the CAR-T field to discuss some of the opportunities and challenges facing our industry.”

Organized by the Alliance for Regenerative Medicine (ARM) and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives from the cell and gene therapy and the scientific communities to discuss the most pressing issues facing the sector.

Download press release(s)

Press release

152.88 Ko

Celyad responds to misleading statements on its patent relating to allogeneic human primar...

Next News

Celyad responds to misleading statements on its patent relating to allogeneic human primar...